Form 4: Neumora Therapeutics CFO Joshua Pinto Sells Shares Under 10b5-1 Trading Plan

Neumora Therapeutics' CFO, Joshua Pinto, sold 15,693 shares of common stock at a weighted average price of $11.394 per share on August 27, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On August 27, 2024, Joshua Pinto, the Chief Financial Officer of Neumora Therapeutics, sold 15,693 shares of the company's common stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on April 18, 2024, and amended on May 22, 2024.
• The shares were sold at prices ranging from $11.1572 to $11.58, with a weighted average price of $11.394.
• Following the transaction, Pinto directly owns 85,000 shares and indirectly owns 138,965 shares through Maple DE Holdings LLC.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale by an executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by company executives are a normal part of corporate governance. The fact that the sale was executed under a 10b5-1 trading plan suggests that the sale was pre-planned and not based on any inside information.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates